Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
RANDOX LABORATORIES
AB Sciex

Companion Diagnostic to Help Development of Cancer Therapy

By Labmedica International staff writers
Posted on 14 Mar 2012
A companion diagnostic test is to be created to aid in the development of an investigational cancer therapy.

Abbott (Abbott Park, Il, USA) will collaborate with Merck (Whitehouse Station, NJ, USA) to evaluate the use of a fluorescence in situ hybridization (FISH)-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy.

FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help determine which patients are likely to benefit from a particular therapy. FISH technology can identify whether too many, or too few, copies of a particular gene are present in the body's cells, or whether certain genes have rearrangements that play an active role in disease progression. Cancer diagnostics is one of its fastest growing applications.

Abbott will develop a test based on its FISH technology, intended to identify deletions of the TP53 gene in cancer patients. The Abbott FISH assay will be evaluated in clinical trials to help identify patients more likely to respond favorably to Merck’s investigational cancer therapy.

Abbott Molecular is a leader in molecular diagnostics. The company analyses DNA and RNA at the molecular level. "Our goal through this collaboration, and others like it, is to ensure that the right medicine gets to the right patient," said Stafford O’Kelly, head of Abbott’s molecular diagnostics business. "As one of the early pioneers in companion diagnostics, we believe that linking genetic testing with drug development at the earliest stages can increase the effectiveness and predictability of medicines and help physicians make more informed treatment decisions."

Abbott's portfolio of companion diagnostic tests includes the PathVysion HER-2 DNA probe kit, which represents one of the first examples of innovations in the field of personalized medicine. The test is approved for use in selecting breast cancer patients for whom Herceptin (trastuzumab) therapy is being considered. In addition, Abbott's Vysis ALK Break Apart FISH probe kit was approved in 2011 for use in identifying non-small-cell lung cancer patients for Xalkori (crizotinib) treatment.

Related Links:

Abbott
Merck


PURITAN MEDICAL
ADVANCED INSTRUMENTS
GREINER-BIO-ONE
BioConferenceLive

Channels

Clinical Chemistry

view channel

Five-Minute Kit-on-a-Lid Assay Detects Asthma from Whole Blood

A team of bioengineers has developed a simple, hand-held device that enables diagnosis of asthma from a single drop of blood. The "kit-on-a-lid-assay (KOALA)" microfluidic technology used to perform the test is the brain child of investigators at the University of Wisconsin (Madison, USA). KOALA capitalizes on differences... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel
Image: The Infinium HumanMethylation27 BeadChip Kit uses the Infinium Methylation Assay and is compatible with the iScan, HiScan, and Bead Array Reader systems (Photo courtesy of Illumina).

Methylated DNA Blood Test Monitors Breast Cancer Progress and Treatment Response

An advanced assay that measures DNA hypermethylatation in blood samples can diagnose advanced breast cancer, as well as monitor tumor burden and treatment response in women with metastatic breast tumors.... Read more

Industry News

view channel

Bio-Rad Acquires GnuBIO and Fast Integrated DNA Sequencing Platform

Global life science and clinical diagnostics company Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has purchased GnuBIO, Inc. (Cambridge, MA. USA), a privately-held company that has developed a novel droplet-based DNA sequencing technology and a system that incorporates all DNA sequencing functions into a single, integrated... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.